← SynDRA
AMBRISENTAN
SynDRA canonical compound SYN0003780 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | EDNRB |
|---|
| Mechanism of action | Endothelin receptor antagonist |
|---|
| Indication | pulmonary arterial hypertension (PAH) |
|---|
| Disease area | pulmonary |
|---|
All known targets
- EDNRA
- EDNRB
- CYP2C19
- CYP3A4
- CYP3A5
- SLCO1B3
Mechanisms of action (all sources)
- Endothelin receptor antagonist
- EDNRB ANTAGONIST
- Endothelin receptor, ET-A/ET-B antagonist
- EDNRA ANTAGONIST
Drug classes
- Endothelin Receptor Antagonists
- Endothelin Receptor Antagonist
- Antihypertensive Agents
- Cardiovascular Agents
ATC classes
- C02K · OTHER ANTIHYPERTENSIVES
Cross-references
Synonyms
- LU208075
- LU 208075
- letairis
- volibris
- GSK-1325760
- GSK-1325760A
- GSK1325760
- GSK1325760A
- LU-208075
- Ambrisentan mylan
- Letairis
- Volibris
- Ambrisentan [INN]
- Gilead brand of ambrisentan
- BSF-208075
- BSF208075
- Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe
- (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid
- 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid
- 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
- 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
- HW6NV07QEC
- AMBRISENTAN, (+)-
- GSK 1325760
- GSK 1325760A
- BSF 208075
- DTXCID2026282
- ambrisentanum
- Pulmonext
- (S)-ambrisentan
- (+)-ambrisentan
- (-)-ambrisentan
- RefChem:56361
- C02KX02
- C22H22N2O4
- MFCD09842330
- CAS-177036-94-1
- UNII-HW6NV07QEC
Reported adverse events
- Flushing
- Sinusitis
- Nasal congestion
- Headache
- Cough
- Bronchitis
- Dyspepsia
Look up AMBRISENTAN in the interactive SynDRA portal →